Outlook Therapeutics Inc Financials
Outlook Therapeutics Inc (OTLK) reported $1.4M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Outlook Therapeutics remains a cash-funded development business, with $1.4M of sales far below its operating burn.
In the latest year, reported revenue was only$1.4M while operating cash flow was-$51.8M , so the income statement is beginning to show sales but not a self-funding commercial engine. Even with burn lower than the prior year, financing inflows of$45.0M still trailed that outflow and cash ended at$8.1M , showing the business is still sustained mainly by capital raises.
The liquidity position tightened from 3.2x to 0.4x, which means near-term obligations now sit against a much thinner working-capital buffer. With negative equity and liabilities above assets, the balance sheet offers little cushion if funding windows narrow.
The spending mix changed meaningfully: R&D fell from
Financial Health Signals
Outlook Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Outlook Therapeutics Inc scores -57.51, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($151.3M) relative to total liabilities ($50.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Outlook Therapeutics Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Outlook Therapeutics Inc reported a net loss of $62.4M while operations used $51.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Outlook Therapeutics Inc reported an operating loss of $67.1M against $283K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Outlook Therapeutics Inc generated $1.4M in revenue in fiscal year 2025.
Outlook Therapeutics Inc's EBITDA was -$66.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 6.5% from the prior year.
Outlook Therapeutics Inc reported -$62.4M in net income in fiscal year 2025. This represents an increase of 17.2% from the prior year.
Outlook Therapeutics Inc earned -$1.79 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Outlook Therapeutics Inc held $8.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Outlook Therapeutics Inc's gross margin was 4.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Capital Allocation
Outlook Therapeutics Inc invested $27.2M in research and development in fiscal year 2025. This represents a decrease of 34.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
OTLK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9K-93.2% | $127K | N/A | N/A | $1.5M | N/A | N/A | N/A |
| Cost of Revenue | $17K-88.6% | $149K+404.0% | $30K | N/A | $440K | N/A | N/A | N/A |
| Gross Profit | -$8K+62.2% | -$22K+98.2% | -$1.2M | N/A | $1.1M | N/A | N/A | N/A |
| R&D Expenses | $3.3M-27.8% | $4.5M+23.8% | $3.6M | N/A | $7.1M+61.9% | $4.4M-54.4% | $9.7M | N/A |
| SG&A Expenses | $7.6M-20.6% | $9.5M+10.4% | $8.6M | N/A | $9.7M+21.2% | $8.0M-33.2% | $11.9M | N/A |
| Operating Income | -$10.8M+22.9% | -$14.0M-4.0% | -$13.5M | N/A | -$15.7M-27.1% | -$12.4M+42.7% | -$21.6M | N/A |
| Interest Expense | $7+133.3% | $3 | $0 | N/A | -$49K-166.7% | -$19K-137.9% | $49K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | $3K | N/A | N/A |
| Net Income | -$20.3M-356.3% | -$4.5M+80.7% | -$23.1M | N/A | -$20.2M+56.5% | -$46.4M-366.8% | $17.4M | N/A |
| EPS (Diluted) | -$0.15 | -$0.05+86.8% | -$0.38-100.0% | -$0.19+65.5% | -$0.55+63.3% | -$1.50-308.3% | $0.72-5.3% | $0.76 |
OTLK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $26.2M+19.6% | $21.9M+20.0% | $18.2M-1.9% | $18.6M-17.0% | $22.4M+17.4% | $19.1M+12.2% | $17.0M-41.0% | $28.8M |
| Current Assets | $23.2M+10.8% | $20.9M+21.8% | $17.2M-1.3% | $17.4M-17.6% | $21.1M+18.5% | $17.8M+13.7% | $15.7M-42.9% | $27.4M |
| Cash & Equivalents | $11.2M+45.1% | $7.7M-10.7% | $8.7M+7.4% | $8.1M-9.2% | $8.9M+17.8% | $7.6M+32.5% | $5.7M-61.8% | $14.9M |
| Inventory | $5.0M+50.8% | $3.3M-3.3% | $3.5M+3.6% | $3.3M-19.1% | $4.1M+14.5% | $3.6M+15.9% | $3.1M | N/A |
| Accounts Receivable | $1.6M-39.5% | $2.7M+2273.1% | $115K-92.3% | $1.5M-14.9% | $1.8M | N/A | N/A | N/A |
| Total Liabilities | $36.6M-28.1% | $50.9M-10.4% | $56.8M+11.8% | $50.8M-14.8% | $59.6M+15.6% | $51.5M-23.4% | $67.3M-34.0% | $101.9M |
| Current Liabilities | $28.7M-26.2% | $38.9M-20.7% | $49.1M+7.1% | $45.8M+45.5% | $31.5M+26.9% | $24.8M-48.5% | $48.2M+13.4% | $42.6M |
| Total Equity | -$10.4M+64.2% | -$29.0M+24.8% | -$38.5M-19.8% | -$32.2M+13.5% | -$37.2M-14.6% | -$32.5M+35.4% | -$50.3M+31.2% | -$73.1M |
| Retained Earnings | -$653.5M-3.2% | -$633.2M-0.7% | -$628.8M-3.8% | -$605.7M-2.2% | -$592.4M-3.5% | -$572.3M-8.8% | -$525.9M+3.2% | -$543.3M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
OTLK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$21.0M-168.4% | -$7.8M+47.6% | -$14.9M-20.7% | -$12.4M-4.0% | -$11.9M+28.2% | -$16.6M-51.2% | -$11.0M+35.4% | -$17.0M |
| Financing Cash Flow | $26.6M+285.6% | $6.9M-55.6% | $15.5M+34.4% | $11.6M-12.7% | $13.2M-28.2% | $18.4M+958.2% | $1.7M+1615.7% | -$115K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
OTLK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -95.0%-77.8pp | -17.2% | N/A | N/A | 70.8% | N/A | N/A | N/A |
| Operating Margin | -124255.3% | -11006.8% | N/A | N/A | -1046.2% | N/A | N/A | N/A |
| Net Margin | -233554.8% | -3494.3% | N/A | N/A | -1338.8% | N/A | N/A | N/A |
| Return on Assets | -77.6%-57.3pp | -20.3%+106.1pp | -126.4% | N/A | -90.0%+153.0pp | -243.0%-345.2pp | 102.2% | N/A |
| Current Ratio | 0.81+0.3x | 0.54+0.2x | 0.350.0x | 0.38-0.3x | 0.670.0x | 0.72+0.4x | 0.32-0.3x | 0.64 |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$32.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.38), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Outlook Therapeutics Inc Ranks
Frequently Asked Questions
What is Outlook Therapeutics Inc's annual revenue?
Outlook Therapeutics Inc (OTLK) reported $1.4M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Outlook Therapeutics Inc profitable?
No, Outlook Therapeutics Inc (OTLK) reported a net income of -$62.4M in fiscal year 2025.
What is Outlook Therapeutics Inc's EBITDA?
Outlook Therapeutics Inc (OTLK) had EBITDA of -$66.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Outlook Therapeutics Inc's gross margin?
Outlook Therapeutics Inc (OTLK) had a gross margin of 4.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Outlook Therapeutics Inc's operating cash flow?
Outlook Therapeutics Inc (OTLK) recorded an outflow of $51.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Outlook Therapeutics Inc's total assets?
Outlook Therapeutics Inc (OTLK) had $18.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Outlook Therapeutics Inc spend on research and development?
Outlook Therapeutics Inc (OTLK) invested $27.2M in research and development during fiscal year 2025.
What is Outlook Therapeutics Inc's current ratio?
Outlook Therapeutics Inc (OTLK) had a current ratio of 0.38 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Outlook Therapeutics Inc's return on assets (ROA)?
Outlook Therapeutics Inc (OTLK) had a return on assets of -335.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Outlook Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Outlook Therapeutics Inc (OTLK) held $8.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $51.8M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Outlook Therapeutics Inc's debt-to-equity ratio negative or not reported?
Outlook Therapeutics Inc (OTLK) has negative shareholder equity of -$32.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Outlook Therapeutics Inc's Altman Z-Score?
Outlook Therapeutics Inc (OTLK) has an Altman Z-Score of -57.51, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Outlook Therapeutics Inc's Piotroski F-Score?
Outlook Therapeutics Inc (OTLK) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Outlook Therapeutics Inc's earnings high quality?
Outlook Therapeutics Inc (OTLK) reported a net loss of $62.4M while operations used $51.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Outlook Therapeutics Inc cover its interest payments?
Outlook Therapeutics Inc (OTLK) reported an operating loss of $67.1M against $283K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.